Abcodia and AstraZeneca China fight for earlier cancer detection
Cambridge UK business Abcodia, a leader in early cancer detection, has formed a strategic partnership with AstraZeneca China focusing on the early detection of ovarian cancer.
With Abcodia’s ROCA Test as the central technology the parties will collaborate to establish ovarian cancer early detection networks across China.
The intent of the collaboration fits strategically with AstraZeneca’s mission to improve cancer outcomes in support of the Chinese government’s ‘Healthy China 2030’ initiative, which includes a focus on early screening, early diagnosis and early treatment, reducing cancer morbidity and mortality and improving the quality of life of patients.
The announcement follows on from Abcodia’s commitment to locate its China subsidiary in Wuxi, on the newly formed I·Campus, which has been created by Wuxi National High-Tech Industrial Development Zone and AstraZeneca China.
Abcodia has also now secured a business licence for its Abcodia subsidiary and now plans to secure ‘on the ground’ expertise to support its expanded footprint.
With a population of over 170 million women in China over the age of 50, ovarian cancer will continue to pose significant burden on individuals and Chinese healthcare systems. Recent data released from the China National Cancer Centre reaffirmed 17,000 deaths from ovarian cancer in 2015 and 34,000 new cases diagnosed annually.
Recurrence of ovarian cancer occurs in over 70 per cent of treatment of all patients, and prolonged illness is painful, and treatment is very costly.
Dr Julie Barnes, CEO of Abcodia said: “This partnership with AstraZeneca China is another key step forward in helping us establish our innovative early detection product in China.
“We are excited to work closely with AstraZeneca China’s oncology business unit and clinical experts from hospitals across China to define the best practical solution to allow access for patients.
“The timing of this partnership alongside the recent approval of AstraZeneca’s PARP inhibitor, Lynparza for maintenance therapy for ovarian cancer holds great promise for transforming the management and outcomes of ovarian cancer.”
Tina Xu, VP of AstraZeneca China, head of Digital and Commercial Innovation added: “Wuxi International Life Science Innovation Campus is a platform developed to gather global healthcare wisdom and innovative forces.
“We are delighted that Abcodia has now secured its business license to establish its operations from the I·Campus and under this additional strategic partnership, we look forward to working closely with Abcodia in the field of ovarian cancer. Aiming to build a life science innovation ecosystem with our partners, we hope to benefit patients in China and around the world.”
Dr Andy Richards, chairman of Abcodia said: “I have been truly impressed at the way that the AstraZeneca team in China has worked with Abcodia. The AstraZeneca vision for integrated oncology care which includes early detection and diagnosis is important and ambitious and will result in improved outcomes. In ovarian cancer this vision is highly aligned with that of Abcodia.
“The Abcodia team is looking forward to a deep and long-term collaboration with AstraZeneca China and to working with the dynamic community that is being created on the I·Campus.”